From: Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Drug | Brand name | Manufacturer | Targets | Applications of diseases | Approved years |
---|---|---|---|---|---|
Trametinib | Mekinist | GlaxoSmithKline | MEK1/2 | Unresectable or metastatic BRAF V600E/K + melanoma | 2013 [153] |
Combined with dabrafenib for the same condition above | 2014 [154] | ||||
Combined with dabrafenib for metastatic BRAF V600E + NSCLC who received previous treatment with chemotherapy | 2017 | ||||
Combined with dabrafenib for locally advanced or metastatic BRAF V600E + ATC with no locoregional treatment options | 2018 [155] | ||||
Cobimetinib | Cotellic | Genentech Inc | MEK1/2 | Combined with vemurafenib for BRAF V600E/K + advanced or unresectable melanoma | 2015 [156] |
Binimetinib | Mektovi | Array BioPharma Inc | MEK1/2 | Combined with encorafenib for unresectable or metastatic BRAF V600E/K + melanoma | 2018 [157] |
Selumetinib | Koselugo | AstraZeneca and Merck | MEK1/2 | Pediatric patients (≥ 2 years old) with symptomatic, inoperable NF1 plexiform neurofibromas | 2020 [158] |